Ara
Toplam kayıt 48, listelenen: 41-48
Clinicopathological and survival characteristics of mismatch repair status and PD-1 expression in serous ovarian cancer
(College of Physicians and Surgeons Pakistan, 2023)
Objective: To evaluate the clinicopathological characteristics of mismatch repair (MMR) deficiency and its clinical outcomes by performing immunohistochemistry (IHC) for MMR genes in the serous ovarian cancer (SOC) tumour ...
Survival effect of palliative radiotherapy in patients with metastatic castration-resistant prostate cancer developing oligo-progression under antiandrogen treatment
(Istanbul University, 2023)
Objective: Androgen pathway inhibitors have a significant impact on the treatment of prostate cancer. The treatment approach is controversial in patients who develop oligo-pro-gression under anti-androgen therapy. This ...
The impact of hybrid capture-based comprehensive genomic profiling on treatment strategies in patients with solid tumors
(Turkiye Klinikleri, 2022)
Objective: The development of bioinformatics and comprehensive genomic profiling (CGP) has provided insights into the ap-plicability and functionality of the genomic alterations (GA). In this study, we evaluated the impact ...
The prognostic utility of the metastatic lymph node ratio and the number of regional lymph nodes removed from patients with small bowel adenocarcinomas
(MDPI, 2023)
Background and Objectives: Small bowel adenocarcinomas (SBAs) are rare tumors of the gastrointestinal system. Lymph node metastasis in patients with curatively resected SBAs is associated with poor prognosis. In this study, ...
Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study
(Association of Basic Medical Sciences of FBIH, 2023)
Regorafenib, an oral multikinase inhibitor, has improved survival in metastatic colorectal cancer (mCRC) patients who have progressed on standard therapies. Our study aimed to evaluate prognostic factors influencing ...
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: A multicenter real-life HER2PATH study
(Taylor & Francis Ltd, 2023)
AimTo investigate the pathological complete response (pCR) achieved after neoadjuvant therapy with versus without adding pertuzumab (P) to trastuzumab (H) plus neoadjuvant chemotherapy (NCT) in HER2+ breast cancer (BC) ...
Survival outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical therapy: A multicenter analysis
(Turkiye Klinikleri, 2023)
Background/aim: Oligometastatic disease for nonsmall cell lung cancer (NSCLC) patients is generally thought to represent a better prognosis with a quieter biology, limited number of disease sites and long-term disease ...
Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye
(2024)
According to current evidence, testing for germline BRCA pathogenic variants in newly diagnosed breast cancer (BC) patients has the potential to reduce the burden of the disease through targeted therapies and secondary ...